Overpatented, Overpriced: Lantus

95% of the patent applications on the diabetes drug Lantus
(insulin glargine) were filed after the drug was on the market.
Read our report to find out more.

Read the Report

Join us to stay updated
and help make lifesaving medicines accessible to all